Function and Modulation of Type I Interferons During Respiratory Syncytial Virus Infection

Overview

Journal Vaccines (Basel)

Date 2020 Apr 16

PMID 32290326

Citations 11

Authors

Laura M Stephens

Steven M Varga

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory infections in infants and young children, accounting for an estimated 3 million hospitalizations annually worldwide. Despite the major health burden, there is currently no licensed RSV vaccine. RSV is recognized by a range of cellular receptors including both toll-like receptors (TLR) and retinoic acid-inducible gene-I-like receptors (RIG-I). This interaction initiates signaling through mitochondrial antiviral signaling (MAVS) and interferon regulatory factor (IRF) proteins, resulting in the induction of type I interferons (IFN). Early viral control is mediated by either IFN-α or IFN-β signaling through the IFN receptor (IFNAR), inducing the production of antiviral interferon-stimulating genes (ISGs). Type I IFNs also initiate the early production of proinflammatory cytokines including interleukin 6 (IL-6), tumor necrosis factor (TNF), and IFN-γ. Type I IFN levels correlate with age, and inadequate production may be a critical factor in facilitating the increased RSV disease severity observed in infants. Here, we review the current literature on the function of type I IFNs in RSV pathogenesis, as well as their involvement in the differential immune responses observed in infants and adults.

Citing Articles

Impact of a Concurrent Respiratory Virus Infection on the Clinical Presentation and Response to Initial Treatment of Kawasaki Disease: A Single-Center Observational Study.

Koyanagi T, Nakagawa R, Okada M, Yokoyama H, Amano S, Shimoyama T J Clin Med. 2025; 14(3).

PMID: 39941446 PMC: 11818305. DOI: 10.3390/jcm14030775.

Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus.

Shan X, Han R, Cheng X, Bing J, Qi Z, Sun S Vaccines (Basel). 2025; 13(1).

PMID: 39852872 PMC: 11769257. DOI: 10.3390/vaccines13010093.

Distinct roles for type I and type III interferons in virulent human metapneumovirus pathogenesis.

Zhang Y, Xu J, Miranda-Katz M, Sojati J, Tollefson S, Manni M PLoS Pathog. 2024; 20(2):e1011840.

PMID: 38315735 PMC: 10868789. DOI: 10.1371/journal.ppat.1011840.

Analyzing the Material Basis of Anti-RSV Efficacy of Lonicerae japonicae Flos Based on the PK-PD Model.

Liang Y, Liu M, Wang Y, Liu L, Gao Y Molecules. 2023; 28(18).

PMID: 37764214 PMC: 10537356. DOI: 10.3390/molecules28186437.

From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.

Miao G, Chen Z, Cao H, Wu W, Chu X, Liu H Biomed Pharmacother. 2023; 158:114208.

PMID: 36800265 PMC: 9805901. DOI: 10.1016/j.biopha.2022.114208.

References

Hall C, Walsh E, Long C, Schnabel K . Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991; 163(4):693-8. DOI: 10.1093/infdis/163.4.693. View

Fischer J, Johnson J, Johnson T, Aung S, Parker R, Graham B . Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol. 1997; 71(11):8672-7. PMC: 192331. DOI: 10.1128/JVI.71.11.8672-8677.1997. View

Nenna R, Fedele G, Frassanito A, Petrarca L, Di Mattia G, Pierangeli A . Increased T-helper Cell 2 Response in Infants With Respiratory Syncytial Virus Bronchiolitis Hospitalized Outside Epidemic Peak. Pediatr Infect Dis J. 2019; 39(1):61-67. DOI: 10.1097/INF.0000000000002505. View

Makris S, Bajorek M, Culley F, Goritzka M, Johansson C . Alveolar Macrophages Can Control Respiratory Syncytial Virus Infection in the Absence of Type I Interferons. J Innate Immun. 2016; 8(5):452-63. PMC: 5322584. DOI: 10.1159/000446824. View

Spann K, Tran K, Chi B, Rabin R, Collins P . Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol. 2004; 78(8):4363-9. PMC: 374276. DOI: 10.1128/jvi.78.8.4363-4369.2004. View

Tang Y, Graham B . Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest. 1994; 94(5):1953-8. PMC: 294611. DOI: 10.1172/JCI117546. View

Swedan S, Musiyenko A, Barik S . Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol. 2009; 83(19):9682-93. PMC: 2748017. DOI: 10.1128/JVI.00715-09. View

Schijf M, Lukens M, Kruijsen D, Van Uden N, Garssen J, Coenjaerts F . Respiratory syncytial virus induced type I IFN production by pDC is regulated by RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific antibodies. PLoS One. 2013; 8(11):e81695. PMC: 3841124. DOI: 10.1371/journal.pone.0081695. View

Kumar H, Kawai T, Akira S . Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1):16-34. DOI: 10.3109/08830185.2010.529976. View

10.

Maher C, Hussell T, Blair E, Ring C, Openshaw P . Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 2004; 6(12):1049-55. DOI: 10.1016/j.micinf.2004.07.001. View

11.

Loo Y, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L . Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol. 2007; 82(1):335-45. PMC: 2224404. DOI: 10.1128/JVI.01080-07. View

12.

Boogaard I, van Oosten M, van Rijt L, Muskens F, Kimman T, Lambrecht B . Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells. Immunology. 2007; 122(1):65-72. PMC: 2265980. DOI: 10.1111/j.1365-2567.2007.02613.x. View

13.

Stevens T, Sinkin R, Hall C, Maniscalco W, McConnochie K . Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000; 154(1):55-61. View

14.

Mitra R, Baviskar P, Duncan-Decocq R, Patel D, Oomens A . The human respiratory syncytial virus matrix protein is required for maturation of viral filaments. J Virol. 2012; 86(8):4432-43. PMC: 3318654. DOI: 10.1128/JVI.06744-11. View

15.

Munir S, Le Nouen C, Luongo C, Buchholz U, Collins P, Bukreyev A . Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol. 2008; 82(17):8780-96. PMC: 2519638. DOI: 10.1128/JVI.00630-08. View

16.

Bendelja K, Gagro A, Bace A, Krsulovic-Hresic V, Drazenovic V, Mlinaric-Galinovic G . Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. Clin Exp Immunol. 2000; 121(2):332-8. PMC: 1905700. DOI: 10.1046/j.1365-2249.2000.01297.x. View

17.

Chen L, Shi M, Deng Q, Liu W, Li Q, Ye P . A multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization. PLoS One. 2020; 15(2):e0228391. PMC: 7034796. DOI: 10.1371/journal.pone.0228391. View

18.

Guerrero-Plata A, Baron S, Poast J, Adegboyega P, Casola A, Garofalo R . Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J Virol. 2005; 79(16):10190-9. PMC: 1182647. DOI: 10.1128/JVI.79.16.10190-10199.2005. View

19.

Lo M, Brazas R, Holtzman M . Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol. 2005; 79(14):9315-9. PMC: 1168759. DOI: 10.1128/JVI.79.14.9315-9319.2005. View

20.

Zhang W, Yang H, Kong X, Mohapatra S, Juan-Vergara H, Hellermann G . Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2004; 11(1):56-62. DOI: 10.1038/nm1174. View